Neil Jay Friedman, MD
Ophthalmology · Menlo Park
- Medicare standing
- 1 flag on the record
- Listed below.
- Plans that list them
- Not verified
- Not the same as out of network.
- Office
- 1
On the public record
- Has dropped Medicare — you would pay privately
Offices
1 location
Hospitals listed: Stanford Health Care. That is not proof they admit you there this week.
Plan participation
Not verified
We could not verify current plan participation for this doctor. This does not mean they are out of network. Call Dr. Friedman’s office to ask if they take your plan before you enroll.
Hospitals they work in
1 hospital
These rate the hospital, not this clinician. Most measures at most hospitals are no different from the national rate.
- Stanford Health CareStanford, CAAcute Care Hospital · Voluntary non-profit - Private · Has an emergency departmentPart of Stanford Health Care, which runs 3 hospitalsHome of Stanford Cancer Institute, a National Cancer Institute designated comprehensive cancer centrePatients rate it 4 of 5 · 83% would definitely recommend itOverall rating: 5 of 5 starsWorse than the national rate — Perioperative pulmonary embolism or deep vein thrombosis rate: 5.31 (4.24 to 6.37) · 8,661 cases, Jul 2022 – Jun 2024Worse than the national rate — Rate of inpatient admissions for patients receiving outpatient chemotherapy: 14.1 (12.7 to 15.7) · 2,191 cases, Jan 2024 – Dec 2024Better than the national rate — Postoperative respiratory failure rate: 4.08 (1.95 to 6.21) · 5,296 cases, Jul 2022 – Jun 2024Better than the national rate — Catheter Associated Urinary Tract Infections (ICU + select Wards): 0.317, Oct 2024 – Sep 2025Better than the national rate — Clostridium Difficile (C.Diff): 0.446, Oct 2024 – Sep 2025Better than the national rate — SSI - Colon Surgery: 0.241, Oct 2024 – Sep 2025Better than the national rate — Ratio of unplanned hospital visits after hospital outpatient surgery: 0.7 (0.6 to 0.9) · 3,348 cases, Jan 2024 – Dec 2024
See every measure and the patient survey for Stanford Health Care
Behind the star rating — Deaths: 5 better, 3 the same, 0 worse of 8 measures. Safety: 3 better, 5 the same, 0 worse of 8 measures. Readmissions: 2 better, 5 the same, 4 worse of 11 measures. The star rating is worked out from an earlier period than the measures below, so the two can disagree.
| Perioperative pulmonary embolism or deep vein thrombosis rateComplications and deaths | 5.31 (4.24 to 6.37) · 8,661 cases | Worse | Jul 2022 – Jun 2024 |
| Rate of inpatient admissions for patients receiving outpatient chemotherapyUnplanned return visits | 14.1 (12.7 to 15.7) · 2,191 cases | Worse | Jan 2024 – Dec 2024 |
| Postoperative respiratory failure rateComplications and deaths | 4.08 (1.95 to 6.21) · 5,296 cases | Better | Jul 2022 – Jun 2024 |
| Catheter Associated Urinary Tract Infections (ICU + select Wards)Infections | 0.317 | Better | Oct 2024 – Sep 2025 |
| Clostridium Difficile (C.Diff)Infections | 0.446 | Better | Oct 2024 – Sep 2025 |
| SSI - Colon SurgeryInfections | 0.241 | Better | Oct 2024 – Sep 2025 |
| Ratio of unplanned hospital visits after hospital outpatient surgeryUnplanned return visits | 0.7 (0.6 to 0.9) · 3,348 cases | Better | Jan 2024 – Dec 2024 |
| Abdominopelvic accidental puncture or laceration rateComplications and deaths | 1.06 (0.45 to 1.67) · 5,374 cases | No different | Jul 2022 – Jun 2024 |
| CMS Medicare PSI 90: Patient safety and adverse events compositeComplications and deaths | 0.86 (0.72 to 1) | No different | Jul 2022 – Jun 2024 |
| Death rate among surgical inpatients with serious treatable complicationsComplications and deaths | 166.09 (137.88 to 194.3) · 470 cases | No different | Jul 2022 – Jun 2024 |
| Death rate for CABG surgery patientsComplications and deaths | 1.1 · 192 cases | None | Jul 2022 – Jun 2025 |
| Death rate for COPD patientsComplications and deaths | 6.4 · 146 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart attack patientsComplications and deaths | 9.7 · 253 cases | None | Jul 2022 – Jun 2025 |
| Death rate for heart failure patientsComplications and deaths | 6.3 · 880 cases | None | Jul 2022 – Jun 2025 |
| Death rate for pneumonia patientsComplications and deaths | 10.3 · 935 cases | None | Jul 2022 – Jun 2025 |
| Death rate for stroke patientsComplications and deaths | 8.7 · 501 cases | None | Jul 2023 – Jun 2025 |
| Hybrid Hospital-Wide All-Cause Risk Standardized Mortality RateComplications and deaths | 2.1 · 7,730 cases | None | Jul 2024 – Jun 2025 |
| Iatrogenic pneumothorax rateComplications and deaths | 0.13 (0 to 0.27) · 20,799 cases | No different | Jul 2022 – Jun 2024 |
| In-hospital fall-associated fracture rateComplications and deaths | 0.28 (0.14 to 0.43) · 23,182 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative acute kidney injury requiring dialysis rateComplications and deaths | 0.94 (0.2 to 1.68) · 5,694 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative hemorrhage or hematoma rateComplications and deaths | 2.36 (1.54 to 3.19) · 7,846 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative sepsis rateComplications and deaths | 5.2 (3.76 to 6.64) · 5,603 cases | No different | Jul 2022 – Jun 2024 |
| Postoperative wound dehiscence rateComplications and deaths | 1.38 (0.23 to 2.53) · 2,211 cases | No different | Jul 2022 – Jun 2024 |
| Pressure ulcer rateComplications and deaths | 0.52 (0.21 to 0.83) · 19,915 cases | No different | Jul 2022 – Jun 2024 |
| Rate of complications for hip/knee replacement patientsComplications and deaths | 3.6 · 416 cases | None | Apr 2023 – Mar 2025 |
| Central Line Associated Bloodstream Infection (ICU + select Wards)Infections | 0.869 | No different | Oct 2024 – Sep 2025 |
| MRSA BacteremiaInfections | 0.857 | No different | Oct 2024 – Sep 2025 |
| SSI - Abdominal HysterectomyInfections | 0.368 | No different | Oct 2024 – Sep 2025 |
| Acute Myocardial Infarction (AMI) 30-Day Readmission RateUnplanned return visits | 16.2 · 247 cases | None | Jul 2023 – Jun 2025 |
| Heart failure (HF) 30-Day Readmission RateUnplanned return visits | 20.5 · 1,021 cases | None | Jul 2023 – Jun 2025 |
| Hospital return days for heart attack patientsUnplanned return visits | 47.8 · 258 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for heart failure patientsUnplanned return visits | -1.6 · 990 cases | None | Jul 2022 – Jun 2025 |
| Hospital return days for pneumonia patientsUnplanned return visits | 20.8 · 976 cases | None | Jul 2022 – Jun 2025 |
| Pneumonia (PN) 30-Day Readmission RateUnplanned return visits | 16.5 · 959 cases | None | Jul 2023 – Jun 2025 |
| Rate of emergency department (ED) visits for patients receiving outpatient chemotherapyUnplanned return visits | 5.2 (4.4 to 6.2) · 2,191 cases | No different | Jan 2024 – Dec 2024 |
| Rate of readmission after hip/knee replacementUnplanned return visits | 5.1 · 425 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for CABGUnplanned return visits | 9.6 · 158 cases | None | Jul 2023 – Jun 2025 |
| Rate of readmission for chronic obstructive pulmonary disease (COPD) patientsUnplanned return visits | 19.6 · 183 cases | None | Jul 2023 – Jun 2025 |
| Rate of unplanned hospital visits after colonoscopy (per 1,000 colonoscopies)Unplanned return visits | 12.7 (10.4 to 15.4) · 4,578 cases | No different | Jan 2022 – Dec 2024 |
What patients said (6,810 patients answered, 25% of those asked)
| Cleanliness | 4 |
| Nurse communication | 4 |
| Doctor communication | 4 |
| Communication about medicines | 3 |
| Discharge information | 4 |
| Overall hospital rating | 4 |
| Quietness | 2 |
| Recommend hospital | 5 |
| Room was "always" clean | 75% |
| Nurses "always" communicated well | 82% |
| Doctors "always" communicated well | 81% |
| Staff "always" explained | 63% |
| Yes, staff "did" give patients this information | 89% |
| Yes, staff "did" give patients information about help after discharge | 89% |
| Doctors "always" explained things so they could understand | 76% |
| Doctors "always" listened carefully | 80% |
| Doctors "always" treated them with courtesy and respect | 87% |
| Patients who gave a rating of "9" or "10" (high) | 79% |
| Staff "always" explained new medications | 76% |
| Nurses "always" explained things so they could understand | 77% |
| Nurses "always" listened carefully | 79% |
| Nurses "always" treated them with courtesy and respect | 88% |
| "Always" quiet at night | 53% |
| "YES", patients would definitely recommend the hospital | 83% |
| Staff "always" explained possible side effects | 50% |
| Yes, staff "did" give patients information about possible symptoms | 90% |
Original Medicare doctor bills
$166,521
Medicare paid this office $166,521 for 758 people.
This is what Medicare paid the clinician — not Medicare Advantage, and not the pharmacy.
| Established patient complete exam of visual system | 582 | $64,236 | $103 |
| Established patient problem focused exam of visual system | 299 | $34,738 | $74 |
| Removal of cataract with insertion of prosthetic lens | 29 | $18,693 | $492 |
| New patient complete exam of visual system | 100 | $10,608 | $106 |
| Exam of visual field with extended testing | 172 | $8,830 | $47 |
See all 15 services
| Established patient complete exam of visual system | 582 | $64,236 | $103 |
| Established patient problem focused exam of visual system | 299 | $34,738 | $74 |
| Removal of cataract with insertion of prosthetic lens | 29 | $18,693 | $492 |
| New patient complete exam of visual system | 100 | $10,608 | $106 |
| Exam of visual field with extended testing | 172 | $8,830 | $47 |
| Imaging of optic nerve | 198 | $5,837 | $29 |
| Removal of recurring cataract in lens capsule using a laser | 15 | $5,122 | $285 |
| Imaging of retina | 106 | $4,118 | $34 |
| Measurement of corneal curvature and depth of eye | 40 | $1,987 | $35 |
| Short return visit | 22 | $1,562 | $52 |
| Exam to measure eye deviation and range of motion | 22 | $1,342 | $58 |
| New patient visit (30+ min) | 12 | $877 | $73 |
| Extended exam of the back part of the eye with retinal drawing | 18 | $522 | $21 |
| Exam of the internal drainage system of eye | 16 | $395 | $25 |
| Ultrasound scan of cornea to determine thickness | 42 | $389 | $9 |
Procedures Medicare counted
| Cataract surgery | 39 | More than 59% of doctors who do this |
Who their Medicare patients are
758 Original Medicare patients in 2024. Average age 79 · Under 65 0% · 85 and older 23% · Women 61% · Health risk score 0.88. At or below the middle of the specialty; the typical ophthalmology clinician is at 1.16.
Conditions among them: High blood pressure 58% · Coronary heart disease 24% · Cancer 18% · Atrial fibrillation 16% · Chronic kidney disease 14% · Diabetes 13% · Heart failure 8% · Depression 8% · COPD 7% · Stroke 4% · Dementia 3%.
The office billed $275,519, Medicare allowed $238,263 and paid $166,521; for 2,012 services of 25 kinds.
Original Medicare patients only. A risk score of 1.0 is the average Medicare patient; higher means sicker. Any count under 11 is hidden.
Year by year
| 2024 | 758 | 2,012 | 79 | 0.88 | $275,519 | $166,521 |
| 2023 | 761 | 2,106 | 79 | 0.94 | $285,632 | $176,687 |
| 2022 | 686 | 1,815 | 78 | 0.87 | $287,088 | $176,261 |
| 2021 | 617 | 1,684 | 78 | 0.87 | $280,740 | $175,720 |
| 2020 | 451 | 1,161 | 78 | 0.98 | $174,595 | $102,932 |
| 2019 | 547 | 1,415 | 78 | 0.91 | $234,695 | $144,106 |
| 2018 | 544 | 1,329 | 78 | 0.93 | $231,609 | $136,863 |
| 2017 | 519 | 1,321 | 78 | 0.92 | $242,795 | $146,924 |
| 2016 | 535 | 1,342 | 77 | 0.91 | $253,088 | $152,163 |
| 2015 | 539 | 1,367 | 78 | 0.89 | $233,187 | $139,034 |
| 2014 | 537 | 1,352 | 77 | 0.83 | $230,640 | $138,915 |
| 2013 | 479 | 1,227 | 77 | 0.85 | $216,595 | $132,206 |
Original Medicare only. A service billed for fewer than 11 people in a year is hidden, so the lines can add up to less than the year's total.
See the services billed each year
2023: 16 services
| Established patient complete exam of visual system | 575 | $61,622 | $101 |
| Established patient problem focused exam of visual system | 341 | $39,196 | $75 |
| Removal of cataract with insertion of prosthetic lens | 40 | $28,664 | $494 |
| New patient complete exam of visual system | 106 | $12,034 | $114 |
| Exam of visual field with extended testing | 190 | $10,253 | $48 |
| Imaging of optic nerve | 180 | $5,249 | $29 |
| Removal of recurring cataract in lens capsule using a laser | 12 | $4,053 | $290 |
| Imaging of retina | 104 | $3,733 | $35 |
| Measurement of corneal curvature and depth of eye | 37 | $2,010 | $36 |
| Short return visit | 26 | $1,808 | $48 |
| Pattern recording of retinal electrical responses to external stimuli with interpretation and report | 27 | $1,791 | $66 |
| Exam to measure eye deviation and range of motion | 21 | $1,251 | $57 |
| New patient visit (30+ min) | 11 | $698 | $63 |
| Exam of the internal drainage system of eye | 28 | $662 | $23 |
| Extended exam of the back part of the eye with retinal drawing | 20 | $571 | $21 |
| Ultrasound scan of cornea to determine thickness | 50 | $413 | $8 |
2022: 15 services
| Established patient complete exam of visual system | 477 | $51,029 | $98 |
| Removal of cataract with insertion of prosthetic lens | 58 | $45,849 | $493 |
| Established patient problem focused exam of visual system | 260 | $28,825 | $74 |
| New patient complete exam of visual system | 114 | $12,456 | $109 |
| Removal of recurring cataract in lens capsule using a laser | 24 | $7,984 | $285 |
| Exam of visual field with extended testing | 140 | $7,098 | $46 |
| Imaging of optic nerve | 130 | $3,912 | $30 |
| Imaging of retina | 88 | $3,151 | $32 |
| Measurement of corneal curvature and depth of eye | 57 | $2,973 | $35 |
| Short return visit | 22 | $1,375 | $49 |
| New patient visit (30+ min) | 12 | $1,093 | $91 |
| Exam to measure eye deviation and range of motion | 13 | $754 | $54 |
| Extended exam of the back part of the eye with retinal drawing | 27 | $611 | $17 |
| Exam of the internal drainage system of eye | 18 | $462 | $24 |
| Ultrasound scan of cornea to determine thickness | 35 | $321 | $9 |
2021: 15 services
| Removal of cataract with insertion of prosthetic lens | 62 | $46,844 | $504 |
| Established patient complete exam of visual system | 425 | $46,818 | $99 |
| Established patient problem focused exam of visual system | 197 | $23,291 | $76 |
| New patient complete exam of visual system | 116 | $13,568 | $117 |
| Removal of recurring cataract in lens capsule using a laser | 31 | $11,280 | $289 |
| Exam of visual field with extended testing | 115 | $6,136 | $48 |
| Measurement of corneal curvature and depth of eye | 64 | $4,097 | $41 |
| Imaging of optic nerve | 107 | $3,174 | $29 |
| Imaging of retina | 85 | $3,161 | $34 |
| New patient visit (30+ min) | 19 | $1,813 | $95 |
| Pattern recording of retinal electrical responses to external stimuli with interpretation and report | 16 | $1,112 | $70 |
| Short return visit | 21 | $1,084 | $52 |
| Extended exam of the back part of the eye with retinal drawing | 28 | $757 | $19 |
| Exam of the internal drainage system of eye | 30 | $676 | $23 |
| Ultrasound scan of cornea to determine thickness | 26 | $249 | $10 |
2020: 12 services
| Established patient complete exam of visual system | 324 | $32,578 | $91 |
| Removal of cataract with insertion of prosthetic lens | 35 | $23,548 | $501 |
| Established patient problem focused exam of visual system | 146 | $15,962 | $69 |
| New patient complete exam of visual system | 65 | $6,570 | $101 |
| Exam of visual field with extended testing | 86 | $4,580 | $49 |
| Imaging of optic nerve | 94 | $2,708 | $29 |
| Measurement of corneal curvature and depth of eye | 38 | $2,613 | $47 |
| Imaging of retina | 46 | $1,600 | $31 |
| Short return visit | 20 | $959 | $42 |
| Exam of the internal drainage system of eye | 28 | $619 | $21 |
| Extended exam of the back part of the eye with retinal drawing | 15 | $439 | $20 |
| Ultrasound scan of cornea to determine thickness | 23 | $226 | $10 |
2019: 16 services
| Established patient complete exam of visual system | 408 | $43,752 | $97 |
| Removal of cataract with insertion of prosthetic lens | 47 | $37,790 | $581 |
| Established patient problem focused exam of visual system | 185 | $21,081 | $71 |
| New patient complete exam of visual system | 62 | $7,279 | $117 |
| Removal of recurring cataract in lens capsule using a laser | 19 | $6,073 | $289 |
| Exam of visual field with extended testing | 101 | $5,566 | $51 |
| Measurement of corneal curvature and depth of eye | 56 | $4,059 | $51 |
| Imaging of optic nerve | 69 | $2,067 | $30 |
| Imaging of retina | 47 | $1,961 | $35 |
| New patient visit (30+ min) | 21 | $1,720 | $82 |
| Short return visit | 29 | $1,639 | $38 |
| Exam of the internal drainage system of eye | 33 | $751 | $22 |
| Exam to measure eye deviation and range of motion | 11 | $741 | $57 |
| Examination of eye by ophthalmoscope with retinal drawing | 25 | $624 | $25 |
| Examination of eye by ophthalmoscope with retinal drawing | 12 | $278 | $23 |
| Ultrasound scan of cornea to determine thickness | 14 | $118 | $8 |
2018: 14 services
| Removal of cataract with insertion of prosthetic lens | 55 | $43,943 | $549 |
| Established patient complete exam of visual system | 390 | $40,385 | $97 |
| Established patient problem focused exam of visual system | 190 | $18,707 | $66 |
| New patient complete exam of visual system | 77 | $8,262 | $107 |
| Removal of recurring cataract in lens capsule using a laser | 17 | $5,589 | $266 |
| Measurement of corneal curvature and depth of eye | 60 | $4,335 | $53 |
| Exam of visual field with extended testing | 80 | $4,080 | $46 |
| Imaging of optic nerve | 69 | $2,055 | $29 |
| Short return visit | 27 | $1,402 | $36 |
| Imaging of retina | 34 | $1,172 | $34 |
| New patient visit (30+ min) | 11 | $814 | $74 |
| Exam of the internal drainage system of eye | 25 | $493 | $20 |
| Examination of eye by ophthalmoscope with retinal drawing | 20 | $443 | $22 |
| Ultrasound scan of cornea to determine thickness | 12 | $125 | $10 |
2017: 13 services
| Removal of cataract with insertion of prosthetic lens | 68 | $52,737 | $561 |
| Established patient complete exam of visual system | 386 | $38,691 | $93 |
| Established patient problem focused exam of visual system | 184 | $19,158 | $70 |
| New patient complete exam of visual system | 65 | $6,985 | $107 |
| Measurement of corneal curvature and depth of eye | 72 | $6,249 | $64 |
| Exam of visual field with extended testing | 97 | $4,967 | $50 |
| Recording of retinal electrical responses to external stimuli | 20 | $2,810 | $140 |
| Imaging of optic nerve | 74 | $2,262 | $31 |
| Short return visit | 30 | $1,577 | $38 |
| Imaging of retina | 28 | $980 | $35 |
| Exam of the internal drainage system of eye | 13 | $288 | $22 |
| Examination of eye by ophthalmoscope with retinal drawing | 12 | $286 | $24 |
| Ultrasound scan of cornea to determine thickness | 14 | $153 | $10 |
2016: 15 services
| Removal of cataract with insertion of prosthetic lens | 68 | $53,797 | $549 |
| Established patient complete exam of visual system | 389 | $39,227 | $95 |
| Established patient problem focused exam of visual system | 214 | $21,048 | $68 |
| Measurement of corneal curvature and depth of eye | 73 | $6,547 | $61 |
| New patient complete exam of visual system | 56 | $6,081 | $109 |
| Exam of visual field with extended testing | 99 | $5,192 | $48 |
| Recording of retinal electrical responses to external stimuli | 24 | $3,224 | $134 |
| Removal of recurring cataract in lens capsule using a laser | 12 | $3,212 | $268 |
| Nerve test | 25 | $3,131 | $125 |
| Short return visit | 25 | $1,166 | $35 |
| Imaging of optic nerve | 32 | $1,082 | $34 |
| Imaging of retina | 19 | $986 | $39 |
| Exam of the internal drainage system of eye | 15 | $350 | $23 |
| Examination of eye by ophthalmoscope with retinal drawing | 13 | $267 | $21 |
| Ultrasound scan of cornea to determine thickness | 11 | $127 | $12 |
2015: 15 services
| Established patient complete exam of visual system | 381 | $37,990 | $93 |
| Removal of cataract with insertion of prosthetic lens | 48 | $34,978 | $555 |
| Established patient problem focused exam of visual system | 203 | $21,580 | $68 |
| New patient complete exam of visual system | 73 | $7,821 | $107 |
| Recording of retinal electrical responses to external stimuli | 46 | $6,309 | $137 |
| Exam of visual field with extended testing | 103 | $5,802 | $51 |
| Measurement of corneal curvature and depth of eye | 54 | $4,921 | $69 |
| Nerve test | 39 | $4,870 | $125 |
| Removal of recurring cataract in lens capsule using a laser | 12 | $3,314 | $276 |
| Short return visit | 51 | $2,427 | $36 |
| Imaging of retina | 16 | $852 | $41 |
| Imaging of optic nerve | 23 | $840 | $37 |
| Exam of the internal drainage system of eye | 25 | $540 | $21 |
| Removal of eyelashes using forceps | 11 | $499 | $36 |
| Examination of eye by ophthalmoscope with retinal drawing | 16 | $369 | $23 |
2014: 15 services
| Removal of cataract with insertion of prosthetic lens | 53 | $43,431 | $571 |
| Established patient complete exam of visual system | 363 | $37,840 | $96 |
| Established patient problem focused exam of visual system | 180 | $18,915 | $67 |
| New patient complete exam of visual system | 83 | $9,215 | $111 |
| Exam of visual field with extended testing | 113 | $6,093 | $50 |
| Measurement of corneal curvature and depth of eye | 56 | $5,423 | $67 |
| Short return visit | 89 | $4,003 | $37 |
| Removal of recurring cataract in lens capsule using a laser | 12 | $3,488 | $268 |
| Short return visit (20+ min) | 24 | $1,966 | $61 |
| New patient visit (30+ min) | 13 | $1,069 | $82 |
| Exam of the internal drainage system of eye | 32 | $770 | $23 |
| Imaging of optic nerve | 20 | $769 | $38 |
| Removal of eyelashes using forceps | 15 | $669 | $42 |
| Examination of eye by ophthalmoscope with retinal drawing | 15 | $362 | $24 |
| Ultrasound scan of cornea to determine thickness | 18 | $214 | $12 |
2013: 14 services
| Removal of cataract with insertion of prosthetic lens | 46 | $38,664 | $569 |
| Established patient complete exam of visual system | 334 | $33,009 | $96 |
| Established patient problem focused exam of visual system | 174 | $18,226 | $71 |
| Exam of visual field with extended testing | 107 | $6,303 | $54 |
| Measurement of corneal curvature and depth of eye | 53 | $5,360 | $68 |
| New patient complete exam of visual system | 39 | $4,727 | $121 |
| Removal of recurring cataract in lens capsule using a laser | 12 | $3,724 | $286 |
| Short return visit | 76 | $3,579 | $38 |
| Short return visit (20+ min) | 48 | $3,029 | $52 |
| New patient visit (45+ min) | 13 | $1,610 | $124 |
| Imaging of optic nerve | 17 | $683 | $40 |
| Exam of the internal drainage system of eye | 25 | $603 | $24 |
| Examination of eye by ophthalmoscope with retinal drawing | 14 | $305 | $22 |
| Ultrasound scan of cornea to determine thickness | 11 | $142 | $13 |
Drugs they prescribed that Part D paid
$129,187
Pharmacies billed $129,187 in 2024.
This is pharmacy cost, not the office bill, and not what patients paid.
Opioids were 0% of their Part D prescriptions (0 of 477) in 2024. At or below the middle of the specialty; the typical ophthalmology clinician is at 0%.
163 generic and 314 brand-name prescriptions · $129,187 in drug cost.
Part D prescriptions only. The opioid rate is opioid prescriptions as a share of all this clinician's Part D prescriptions; surgeons and pain specialists run higher than others, so it is shown against the same specialty.
| Lumigan | 42 | $20,736 | $494 |
| Cequa | 18 | $16,237 | $902 |
| Restasis Multidose | 25 | $15,314 | $613 |
| Rocklatan | 24 | $13,991 | $583 |
| Xiidra | 14 | $9,844 | $703 |
See all 11 drugs
| Lumigan | 42 | $20,736 | $494 |
| Cequa | 18 | $16,237 | $902 |
| Restasis Multidose | 25 | $15,314 | $613 |
| Rocklatan | 24 | $13,991 | $583 |
| Xiidra | 14 | $9,844 | $703 |
| Prolensa | 13 | $5,075 | $390 |
| Brimonidine | 30 | $4,478 | $149 |
| Latanoprost | 77 | $904 | $12 |
| Moxifloxacin | 21 | $406 | $19 |
| Timolol Maleate | 25 | $174 | $7 |
| Dorzolamide | 18 | $148 | $8 |
Year by year
| 2024 | 477 | 119 | 0% (0) | 66% | $129,187 |
| 2023 | 509 | 144 | 0% (0) | 72% | $144,149 |
| 2022 | 484 | 129 | 0% (0) | 72% | $145,733 |
| 2021 | 414 | 126 | 0% (0) | 76% | $121,220 |
| 2020 | 380 | 98 | 0% (0) | 73% | $112,591 |
| 2019 | 399 | 110 | 0% (0) | 81% | $116,920 |
| 2018 | 446 | 115 | 0% (0) | 81% | $112,708 |
| 2017 | 474 | 129 | 0% (0) | 85% | $107,801 |
| 2016 | 525 | 141 | 0% (0) | 88% | $108,279 |
| 2015 | 468 | 110 | 0% (0) | 93% | $98,232 |
| 2014 | 595 | 129 | 0% (0) | 94% | $107,945 |
| 2013 | 589 | 138 | 0% (0) | 94% | $96,315 |
Part D prescriptions only. A drug prescribed to fewer than 11 people in a year is hidden.
See the drugs prescribed each year
2023: 15 drugs
| Lumigan | 52 | $27,227 | $524 |
| Rocklatan | 26 | $15,696 | $604 |
| Cequa | 17 | $14,848 | $873 |
| Prolensa | 36 | $12,902 | $358 |
| Xiidra | 16 | $11,654 | $728 |
| Restasis | 11 | $10,909 | $992 |
| Alphagan P | 26 | $7,147 | $275 |
| Lotemax Sm | 26 | $6,750 | $260 |
| Besivance | 22 | $4,911 | $223 |
| Azopt | 11 | $3,520 | $320 |
| Simbrinza | 11 | $2,627 | $239 |
| Latanoprost | 77 | $2,033 | $26 |
| Moxifloxacin | 24 | $536 | $22 |
| Dorzolamide | 27 | $296 | $11 |
| Timolol Maleate | 26 | $195 | $8 |
2022: 15 drugs
| Lumigan | 55 | $24,573 | $447 |
| Cequa | 16 | $18,890 | $1,181 |
| Prolensa | 41 | $14,094 | $344 |
| Rocklatan | 16 | $11,767 | $735 |
| Besivance | 46 | $9,907 | $215 |
| Alphagan P | 21 | $8,451 | $402 |
| Xiidra | 12 | $8,134 | $678 |
| Brinzolamide | 14 | $4,614 | $330 |
| Travoprost | 30 | $3,999 | $133 |
| Inveltys | 13 | $3,903 | $300 |
| Loteprednol Etabonate | 21 | $3,445 | $164 |
| Latanoprost | 32 | $1,291 | $40 |
| Moxifloxacin | 16 | $442 | $28 |
| Timolol Maleate | 17 | $408 | $24 |
| Dorzolamide | 24 | $315 | $13 |
2021: 16 drugs
| Lumigan | 52 | $22,872 | $440 |
| Cequa | 24 | $16,969 | $707 |
| Restasis | 17 | $13,597 | $800 |
| Prolensa | 38 | $11,546 | $304 |
| Xiidra | 13 | $8,236 | $634 |
| Besivance | 38 | $7,440 | $196 |
| Alphagan P | 14 | $7,180 | $513 |
| Azopt | 13 | $5,063 | $389 |
| Inveltys | 13 | $3,838 | $295 |
| Travoprost | 12 | $2,092 | $174 |
| Latanoprost | 28 | $803 | $29 |
| Moxifloxacin | 18 | $564 | $31 |
| Prednisolone Acetate | 12 | $462 | $39 |
| Dorzolamide | 13 | $364 | $28 |
| Acyclovir | 14 | $277 | $20 |
| Timolol Maleate | 16 | $237 | $15 |
2020: 13 drugs
| Lumigan | 65 | $26,187 | $403 |
| Restasis | 16 | $16,451 | $1,028 |
| Cequa | 21 | $11,724 | $558 |
| Azopt | 25 | $10,881 | $435 |
| Xiidra | 12 | $7,029 | $586 |
| Alphagan P | 14 | $6,157 | $440 |
| Prolensa | 19 | $5,507 | $290 |
| Travoprost | 26 | $4,501 | $173 |
| Besivance | 23 | $4,217 | $183 |
| Lotemax | 13 | $2,752 | $212 |
| Latanoprost | 34 | $822 | $24 |
| Dorzolamide | 17 | $382 | $22 |
| Timolol Maleate | 15 | $200 | $13 |
2019: 13 drugs
| Lumigan | 62 | $25,503 | $411 |
| Restasis | 28 | $21,612 | $772 |
| Lotemax | 54 | $11,568 | $214 |
| Travatan Z | 22 | $8,745 | $398 |
| Azopt | 14 | $7,107 | $508 |
| Xiidra | 12 | $6,691 | $558 |
| Besivance | 36 | $6,163 | $171 |
| Prolensa | 23 | $6,100 | $265 |
| Alphagan P | 12 | $4,420 | $368 |
| Bepreve | 12 | $2,691 | $224 |
| Latanoprost | 26 | $539 | $21 |
| Dorzolamide | 20 | $386 | $19 |
| Timolol Maleate | 11 | $166 | $15 |
2018: 12 drugs
| Lumigan | 83 | $27,477 | $331 |
| Lotemax | 54 | $11,845 | $219 |
| Prolensa | 38 | $9,779 | $257 |
| Xiidra | 14 | $9,518 | $680 |
| Azopt | 23 | $9,224 | $401 |
| Restasis | 17 | $8,652 | $509 |
| Travatan Z | 20 | $7,226 | $361 |
| Besivance | 42 | $6,907 | $164 |
| Alphagan P | 19 | $6,521 | $343 |
| Valacyclovir | 12 | $788 | $66 |
| Latanoprost | 25 | $616 | $25 |
| Dorzolamide | 14 | $314 | $22 |
2017: 12 drugs
| Lumigan | 90 | $27,779 | $309 |
| Lotemax | 61 | $10,650 | $175 |
| Travatan Z | 33 | $10,482 | $318 |
| Restasis | 15 | $9,941 | $663 |
| Prolensa | 38 | $8,789 | $231 |
| Alphagan P | 25 | $7,491 | $300 |
| Azopt | 17 | $7,033 | $414 |
| Besivance | 42 | $6,304 | $150 |
| Xiidra | 12 | $5,784 | $482 |
| Dorzolamide | 25 | $576 | $23 |
| Latanoprost | 16 | $346 | $22 |
| Timolol Maleate | 15 | $253 | $17 |
2016: 12 drugs
| Lumigan | 86 | $21,230 | $247 |
| Lotemax | 71 | $12,133 | $171 |
| Restasis | 15 | $11,253 | $750 |
| Alphagan P | 45 | $10,503 | $233 |
| Azopt | 27 | $9,984 | $370 |
| Prolensa | 44 | $9,389 | $213 |
| Travatan Z | 26 | $8,872 | $341 |
| Besivance | 56 | $7,623 | $136 |
| Pataday | 18 | $2,890 | $161 |
| Latanoprost | 20 | $328 | $16 |
| Dorzolamide | 12 | $299 | $25 |
| Timolol Maleate | 15 | $208 | $14 |
2015: 10 drugs
| Lumigan | 122 | $27,255 | $223 |
| Restasis | 15 | $10,294 | $686 |
| Azopt | 35 | $9,000 | $257 |
| Lotemax | 39 | $6,857 | $176 |
| Alphagan P | 40 | $6,752 | $169 |
| Travatan Z | 19 | $5,407 | $285 |
| Besivance | 36 | $4,930 | $137 |
| Prolensa | 20 | $4,293 | $215 |
| Xalatan | 17 | $2,249 | $132 |
| Timolol Maleate | 12 | $184 | $15 |
2014: 11 drugs
| Lumigan | 129 | $23,194 | $180 |
| Lotemax | 91 | $14,691 | $161 |
| Restasis | 32 | $12,240 | $383 |
| Alphagan P | 49 | $8,247 | $168 |
| Prolensa | 41 | $8,007 | $195 |
| Azopt | 30 | $5,578 | $186 |
| Pataday | 21 | $5,325 | $254 |
| Besivance | 42 | $5,189 | $124 |
| Travatan Z | 13 | $2,593 | $199 |
| Nevanac | 11 | $2,013 | $183 |
| Timolol Maleate | 14 | $114 | $8 |
2013: 14 drugs
| Lumigan | 115 | $20,351 | $177 |
| Lotemax | 104 | $17,741 | $171 |
| Restasis | 43 | $14,569 | $339 |
| Besivance | 49 | $5,242 | $107 |
| Bromday | 26 | $4,509 | $173 |
| Azopt | 24 | $4,332 | $181 |
| Alphagan P | 34 | $4,296 | $126 |
| Lacrisert | 12 | $4,014 | $335 |
| Pataday | 16 | $3,152 | $197 |
| Prolensa | 14 | $2,673 | $191 |
| Travatan Z | 17 | $2,481 | $146 |
| Patanol | 12 | $1,614 | $135 |
| Dorzolamide-Timolol | 15 | $444 | $30 |
| Latanoprost | 12 | $168 | $14 |
Money from drug and device companies
$201 in 2025
| 2025 | 4 | 10 | None | $201 |
| 2024 | 7 | 15 | None | $446 |
| 2023 | 4 | 14 | None | $552 |
| 2022 | 6 | 17 | $1,525 | $1,821 |
| 2021 | 7 | 16 | $4,039 | $4,287 |
| 2020 | 5 | 11 | None | $288 |
| 2019 | 13 | 25 | $3,900 | $4,968 |
Paid work is consulting, speaking, honoraria and royalties, as opposed to meals and travel.
Amaros, Inc.
$36,675
Held by this doctor · 2024 · Common Stock · amount invested $225
Amaros Medical
$36,675
Held by this doctor · 2023, 2022, 2021, 2020, 2019 · Common Stock, Common Stock., Stock Option Exercise, Stock Options With 48-Month Vesting, Common Stock of Amaros Medical, Inc. · amount invested $225
Visant Medical, Inc.
$2,550
Held by this doctor · 2022, 2021, 2020, 2019 · Common Stock, Stock Option Exercise., Stock Options With 48-Month Vesting, Common Stock of Visant Medical, Inc. · amount invested $51
Omera Medical, Inc.
$25
Held by this doctor · 2021, 2020 · Common Stock, Stock Options With 48-Month Vesting · amount invested $25
Published ownership or investment in a drug or device company. This is not proof that care is biased.
A payment is not proof that care is biased.
| Bausch & Lomb Americas | Miebo | $103 | 6 payments
|
| Harrow Eye | Vevye | $51 | 2 payments
|
| Dompe US | Oxervate | $25 | 1 payment
|
| Abbvie | Durysta | $23 | 1 payment
|
See all 10 published payments
| Dompe US | Meals · 2025-09-18 | Oxervate | $25 |
| Bausch & Lomb Americas | Meals · 2025-06-23 | Miebo | $14 |
| Bausch & Lomb Americas | Meals · 2025-06-23 | Miebo | $14 |
| Harrow Eye | Meals · 2025-05-19 | Vevye | $33 |
| Bausch & Lomb Americas | Meals · 2025-05-14 | Miebo | $23 |
| Bausch & Lomb Americas | Meals · 2025-05-14 | Xiidra | $18 |
| Abbvie | Meals · 2025-04-01 | Durysta | $23 |
| Bausch & Lomb Americas | Meals · 2025-03-13 | Miebo | $21 |
| Harrow Eye | Meals · 2025-03-04 | Vevye | $18 |
| Bausch & Lomb Americas | Meals · 2025-02-06 | Miebo | $14 |
See earlier years (2024, 2023, 2022, 2021, 2020, 2019)
2024: $446
| Oyster Point Pharma | Tyrvaya | $170 | 3 payments
|
| Bausch & Lomb Americas | Vyzulta | $107 | 6 payments
|
| Alcon Vision | Clareon | $59 | 2 payments
|
| Sun Pharmaceutical Industries | Cequa | $33 | 1 payment
|
| Sight Sciences | Omni Surgical System | $30 | 1 payment
|
| Abbvie | Lumigan | $24 | 1 payment
|
| RxSight | Rxsight Contact Lens | $23 | 1 payment
|
2023: $552
| Oyster Point Pharma | Tyrvaya | $276 | 7 payments
|
| Alcon Vision | Clareon | $138 | 1 payment
|
| Bausch & Lomb Americas | Vyzulta | $83 | 4 payments
|
| Sun Pharmaceutical Industries | Cequa | $55 | 2 payments
|
2022: $1,821
| Johnson & Johnson Surgical Vision | None | $1,525 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $122 | 8 payments
|
| Bausch & Lomb Americas | Prolensa | $71 | 3 payments
|
| Alcon Vision | Rocklatan | $65 | 3 payments
|
| Abbvie | Vuity | $20 | 1 payment
|
| Kala Pharmaceuticals | Inveltys | $18 | 1 payment
|
2021: $4,287
| Johnson & Johnson Surgical Vision | None | $2,739 | 3 payments
|
| Kala Pharmaceuticals | Eysuvis | $1,300 | 1 payment
|
| Aerie Pharmaceuticals | Rhopressa | $80 | 4 payments
|
| Allergan | Restasis Multidose | $62 | 3 payments
|
| Sun Pharmaceutical Industries | Cequa | $45 | 2 payments
|
| Bausch & Lomb a division of Bausch Health US | Vyzulta | $38 | 2 payments
|
| Dompe US | Oxervate | $24 | 1 payment
|
2020: $288
| Sun Pharmaceutical Industries | Cequa | $182 | 5 payments
|
| Aerie Pharmaceuticals | Rhopressa | $49 | 3 payments
|
| Novartis Pharmaceuticals | Xiidra | $23 | 1 payment
|
| Bausch & Lomb a division of Bausch Health US | Lotemax Sm | $20 | 1 payment
|
| Mallinckrodt Hospital Products | Acthar | $15 | 1 payment
|
2019: $4,968
| Sight Sciences | Tearcare | $2,600 | 1 payment
|
| Johnson & Johnson Surgical Vision | Tecnis 1-Piece Iol | $1,300 | 1 payment
|
| Sun Pharmaceutical Industries | Cequa | $242 | 7 payments
|
| Solta Medical a division of Bausch Health US | None | $207 | 2 payments
|
| Dompe US | Oxervate | $149 | 2 payments
|
| Aerie Pharmaceuticals | Rhopressa | $133 | 3 payments
|
| Bausch & Lomb a division of Bausch Health US | Lotemax | $110 | 3 payments
|
| Hoffmann-La Roche | Non-Covered Product | $107 | 1 payment
|
| Omeros | Omidria | $37 | 1 payment
|
| Shire North American Group | Xiidra | $24 | 1 payment
|
| Eyevance Pharmaceuticals | Flarex | $21 | 1 payment
|
| Allergan | Restasis | $19 | 1 payment
|
| AbbVie | Humira | $18 | 1 payment
|
Checkups this office reported
Medicare did not publish checkup rates for this clinician.
- Medicare’s overall office score
- 74.6 / 100
- Scores the office’s reporting and systems. It is not a grade for how the doctor treats you.
Professional record
- NPI
- 1477644334
- Licence
- CA G084315
- Trained
- Harvard Medical School, 1992
- Gender
- Male
More record details
- Sole proprietor
- No
- Medicaid ID
- CA 00G843150
- Taxonomy
- Federal specialty code 207W00000X (207W00000X)
- Mailing address
- 1225 Crane St, Suite 200, Menlo Park, CA, 94025
- NPI first listed
- 2006-09-27
- NPI last updated
- 2015-06-01
This is when the NPI record was last certified, not a medical board exam.